In several preclinical studies performed using drug-naïve melanomas, various drug-tolerant subpopulations have been identified as a part of the response to BRAFV600/MEK inhibition [33], including a subpopulation of MITFlow/NGFRhigh cells [34,35,36]. Here, MAP2K7 is linked to melanoma.